This clinical trial is for adults who have a confirmed diagnosis of solid tumor cancer associated with a risk of recurrence or progression (meaning that the cancer could come back or worsen).
   
This study aims to understand how the investigational Signatera genome blood test is used to care for cancer patients. Researchers want to learn how well the test can spot cancer that is returning, understand how doctors use the test results to make treatment decisions, study how effective the test is for different types of cancer, and support the development of new tests.
   
Participants will give blood samples during their regular doctor visits. Leftover tissue from previous biopsies or surgeries will also be used so participants won't need any new procedures. Researchers will collect information about participants’ health and cancer treatment from their medical records. Everything happens during normal care visits, so participants won't need to make any extra trips to the doctor.
   
Participation in this study could continue for up to two years depending on the time it takes to collect up to 8 standard follow-up blood samples (about one every three months) over the course of a participant’s regular treatment, observation, and monitoring period.